Management of cytomegalovirus infection and disease in liver transplant recipients

Table 2 Estimated incidence of cytomegalovirus disease during the first 12 mo after liver transplantation

	Use of anti-CMV prophylaxis for 3-6 mo
	Yes1	No
CMV D+/R-	12%-30%	44%-65%
CMV D+/R+	2.70%	18.20%
CMV D-/R+	3.90%	7.90%
CMV D-/R-	0%	1%-2%
All patients	4.80%	18%-29%

¹Most cases occur as delayed-onset cytomegalovirus (CMV) disease. CMV disease occurs rarely during prophylaxis with oral valganciclovir. Data adapted from Ref. [4,5,92,104]. D: Donor; R: Recipient.